Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.

Lancet Respir Med · 2022 · PMC8635458 · PMID 34863332

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Other secondary outcomes, including mortality, time to recovery, and time to two-point improvement did not achieve significance in the overall population or in those treated with remdesivir or remdesivir and steroids ( table 2 , appendix pp 4–5, 10, 12, 14 ).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.